Madrigal Pharmaceuticals (NASDAQ:MDGL) Upgraded to “Sell” at StockNews.com
StockNews.com upgraded shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) to a sell rating in a research report released on Saturday morning. A number of other research analysts also recently issued reports on MDGL. Citigroup reduced their price objective on Madrigal Pharmaceuticals from $382.00 to $371.00 and set a buy rating for the company in […]
More Stories
JBR Co Financial Management Inc Decreases Position in Starbucks Co. (NASDAQ:SBUX)
JBR Co Financial Management Inc decreased its stake in Starbucks Co. (NASDAQ:SBUX – Free Report) by 4.1% in the third...
Willner & Heller LLC Sells 108 Shares of General Dynamics Co. (NYSE:GD)
Willner & Heller LLC lessened its position in General Dynamics Co. (NYSE:GD – Free Report) by 5.3% in the third...
McGlone Suttner Wealth Management Inc. Raises Holdings in Philip Morris International Inc. (NYSE:PM)
McGlone Suttner Wealth Management Inc. lifted its stake in Philip Morris International Inc. (NYSE:PM – Free Report) by 16.7% during...
Ameliora Wealth Management Ltd. Sells 700 Shares of AbbVie Inc. (NYSE:ABBV)
Ameliora Wealth Management Ltd. reduced its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 41.2% during the third quarter,...
Ayrshire Capital Management LLC Has $6.42 Million Stock Holdings in UnitedHealth Group Incorporated (NYSE:UNH)
Ayrshire Capital Management LLC grew its holdings in UnitedHealth Group Incorporated (NYSE:UNH – Free Report) by 0.7% in the third...
Ballew Advisors Inc Invests $219,000 in AbbVie Inc. (NYSE:ABBV)
Ballew Advisors Inc bought a new position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) during the 3rd quarter,...